The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 27, 2019

Filed:

Nov. 25, 2014
Applicant:

Ajou University Industry-academic Cooperation Foundation, Seoul, KR;

Inventors:

You Sun Kim, Suwon-si, KR;

Gi Bang Koo, Seocheon-gun, KR;

Jung Ho Yun, Yeoncheon-gun, KR;

Woo Jung Kim, Osan-si, KR;

Yu Na Jo, Eunpyeong-gu, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 31/706 (2006.01); A61K 45/06 (2006.01); A61K 31/337 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/706 (2013.01); A61K 31/337 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5011 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/9121 (2013.01); G01N 2333/91205 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition for an anticancer adjuvant containing a receptor-interacting protein kinase-3 (RIP3) protein expression inducing agent or activator as an active ingredient. The present invention also provides a method for enhancing cancer cell death, comprising administering a RIP3 protein expression inducing agent or activator in combination with an anticancer drug to cancer cells. Additionally, the present invention relates to a method for screening an anticancer adjuvant which enhances anticancer drug sensitivity by promoting RIP3 expression; and a method for monitoring anticancer drug sensitivity based on RIP3 expression. Therefore, in the case of patients lacking RIP3 expression, the use of a conventional chemotherapeutic agent after inducing RIP3 expression by pretreatment with a demethylating agent may be an effective therapeutic strategy. Also, it is expected that monitoring anticancer drug sensitivity and screening an anticancer adjuvant that enhances anticancer drug sensitivity in anticancer therapy may be an effective strategy.


Find Patent Forward Citations

Loading…